Last reviewed · How we verify
NCT06784713
DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN
trial in COVID - 19 in 127,277 participants. Completed in 23 October 2023.
1 March 2023
Quick facts
| Lead sponsor | University of Tartu |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 127,277 |
| Start date | 27 February 2020 |
| Primary completion | 1 March 2023 |
| Estimated completion | 23 October 2023 |
| Sites | 1 location across Estonia |
Conditions studied
- COVID - 19 — all drugs for COVID - 19 →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
- Post-COVID Conditions — all drugs for Post-COVID Conditions →
- MIS-C Associated With COVID-19 — all drugs for MIS-C Associated With COVID-19 →
Sponsor
University of Tartu
Who can join
Adults 0 Days to 18, any sex, with COVID - 19 or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study focuses on Estonian children under 18 who had COVID-19 from 27.02.2020 to 01.03.2023. The main aim is to find out the risk factors for severe COVID-19 in children. In order to do that the study includes their demographic data, vaccination status, and details about the severity of illness, such as hospitalization and long-term effects of COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06784713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID - 19
Currently open trials in the same condition.
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT07150871 — Impact of Covid-19 on Syphilis · active not recruiting
- NCT07204366 — Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Stu · active not recruiting
Other University of Tartu trials
Trials by the same sponsor.
- NCT07491549 — The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity · NA · recruiting
- NCT07276490 — Central Haemodynamics and Pacing for AV Block · NA · recruiting
- NCT06829004 — Calf Circumference Adjusted for Body Composition to Assess Muscle Mass · not yet recruiting
- NCT06873880 — Integrating BIA and eGFR for Nutritional Status in Hemodialysis Patients · recruiting
- NCT06768788 — Long-term Impact of PE Teacher Interventions on Adolescent Leisure Time Activity and Motivation · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06784713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Tartu
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06784713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing